Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607906 · ClinicalTrials.gov registry record · Phase 1
First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00607906 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 36 participants.
The verdict
NCT00607906, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.
Interventions
- DRUG Placebo
- DRUG SB-756050 immediate release capsule
- DRUG SB-756050 modified release capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-11-16 |
| Est. Completion | 2008-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607906
The ClinicalTrials.gov registry entry for NCT00607906 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00607906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00607906 about?
NCT00607906 is a clinical study titled "First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050". This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT00607906?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-11-16. Estimated completion is 2008-03-10.
What interventions are being tested in trial NCT00607906?
The interventions under investigation include: Placebo (DRUG), SB-756050 immediate release capsule (DRUG), SB-756050 modified release capsule (DRUG).
Who is sponsoring clinical trial NCT00607906?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.